GLG News by Intravascular Ultrasound Users (US)

Ramin EbrahimiDirector of Cardiac Catheterization LabWadsworth VA Medical Center What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Risk Versus Benefit

November 23, 2007

Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com

The pooled analysis of Rimonabant trials point to a significant increase in psychiatric disorders. These studies also point to significant improvements in markers of cardiovascular risk. Risks versus benefits must be considered before the final decision is made on this class of medications.

John Hewett, Partner

John HewettPartnerPacific Interventional What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Speech Recognition in it's Adolescence

September 4, 2007

Philips SpeechMagic Used In Largest Deployment Of Front-End Radiology Speech Recognition In The UK | www.medicalnewstoday.com

Despite large advances in the utility of speech recognition in medicine, the stated benefits are not fully achieved at this time.  The development of this technology promises significant cost savings and improvements in efficiency especially in the radiology department.  The maturation of this technology will be an important symbiosis to the maturation of imaging and other workflow technologies in radiology.  The key to successful use of speech recognition is judicious implementation.

Ramin EbrahimiDirector of Cardiac Catheterization LabWadsworth VA Medical Center What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Good device but not much improvement.

August 31, 2007

St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device | www.medicalnewstoday.com

The repositioning of the hole, also present with the VIP version is a mild improvement to decrease sheath manipulation. Otherwise the device has not changed much in the past few years. While a very good device in general, its primary limitaions listed below still remain. 1. not allowing re-access at the previous access site within 90 days of the index procedure  2. inability to promote means for primary healing of the arteriotomy site (primary healing results in much less scar formation and secondary healing that angioseal provides) and 3. relying on an intravascular component for deployment that stays within the vessel for weeks prior to its resolution  Newer devices such as the STARCLOSE that also are easy to deploy, rely on no intravascular components and potentially provide much better healing process may be the way of future.   

Page : 11 to 3 of 3

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News